Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Elsevier must end its fossil fuel partnerships and subsidies

Elsevier, The Lancet’s publisher, continues to subsidise climate pollution through analytic tools and new journals supporting coal, oil, and gas exploration and extraction—an ongoing partnership that is morally and materially insupportable.

Richard Horton calls climate change the most important existential crisis facing the human species, supported by the unjust burden of mortality and morbidity catalogued in the Lancet Countdown on health and climate change. For human safety, most known oil and gas, and almost all coal, must remain in the ground. Further, the Intergovernmental Panel on Climate Change (IPCC) now identifies unethical gas exploitation as the major barrier to climate action.

On behalf of Climate Health Aotearoa, a national climate change and health research centre in New Zealand, we call on The Lancet’s Editorial Board to demand an end to Elsevier’s support for fossil fuel industries. We urge The Lancet Group to ensure Elsevier upholds the Group’s ethical commitment: that the best science must lead to better lives.

We declare no competing interests.

*Alex Macmillan, Rhys Jones
alex.macmillan@otago.ac.nz

University of Otago, Dunedin 8016, New Zealand (AM); Te Kupenga Hauora Māori, University of Auckland, Auckland, New Zealand (RJ)

1 Horton R. Health and climate. Oct 24, 2019. https://www.youtube.com/watch?v=YEVGNen eVug (accessed Nov 24, 2022).

Publisher’s reply

As a scientific publisher and information analytics company, we take our responsibility seriously. We have been supporting sustainability research and working to reduce our environmental impact for more than 15 years. In 2021, we made a firm pledge to become net zero for all direct and indirect emissions by 2040.

We support the advancement of knowledge about climate change and its impacts through the research that we publish and analytical tools that deliver insights for evidence-based policy, innovation, and action. In 2021, we published Pathways To Net Zero: the impact of clean energy research, a report that we followed up in 2022, ahead of COP27, with Pathways To Net Zero: global south research in the transition to clean energy to analyse the role of clean energy research in the global south.

We have accelerated the transition of our products to focus on renewable energy. Only six of our 2800 journals currently relate to hydrocarbon science, with updated aims and scope to focus on topics such as renewable energy, and carbon capture and storage. We are working to ensure our editorial boards have the right expertise and balanced representation. Our Elsevier Energy Books Teams have adopted Energy With Purpose as their mission, which is a commitment to only commission content that supports and advances the energy transition and the reduction of CO2 emissions.

At Elsevier, we hold ourselves accountable to take climate action and deliver on our net zero pledge. We have made solid progress but know that there is more to do. We will continue to collaborate with the communities we serve and share our progress and learnings, and we welcome feedback from all stakeholders.

I am Executive Vice President of Elsevier Global Communications.

Esra Erkal
e.erkal@elsevier.com
Elsevier, London EC2Y 5AS, UK

For Elsevier’s Pathways to Net Zero reports see https://www. elsevier.com/connect/net-zero-report

For the Lancet Countdown on health and climate change see https://www.thelancet.com/ countdown-health-climate

For IPCC reports see https://www.ipcc.ch/

For more about the Energy Books Team see https://www. elsevier.com/physical-sciences- and-engineering/energy/books/ publish-energy

For more on Climate Health Aotearoa see http://www. climatehealthaotearoa.org.nz/

For The Lancet Group’s pledge see https://www.thelancet.com/about-us

WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed

An essential line of defence in a global living-with-COVID-19 policy is formed by effective therapeutic strategies for vulnerable patients, many of whom are excluded from treatment with nirmatrelvir-ritonavir (sold as Paxlovid, Pfizer) by virtue of their comorbidities or interacting medications. Preliminary data suggest that monoclonal antibodies (mAbs) are highly effective for these groups, and WHO, in its Therapeutics and COVID-19: Living Guideline, has previously conditionally recommended the use of sotrovimab (sold as Xevudy, Vir Biotechnology and GlaxoSmithKline) or casirivimab- imdevimab (sold as Ronapreve, Regeneron) for people at high risk of hospitalisation. However, in a Sept 16, 2022, update, WHO issued a “strong recommendation against” use of these mAbs, stating that they “[do] not neutralize the currently circulating variants of SARS-CoV-2 and their subvariants”.1

This guidance requires an urgent reassessment. Based on analysis of both the existing literature and data presented here, mAbs neutralise circulating variants and remain the best treatment option for many vulnerable patients, offering a high benefit-to-risk ratio.

To measure neutralising capabilities of mAbs, we used live-virus micro-neutralisation assays on Good Clinical Practice-compliant high-throughput platform, calibrated to WHO International Standards2 for anti-SARS-CoV-2 immunoglobulin (WHO/BS/2020.2403 and WHO/ BS/2022.2427, which we contributed to the calibration of) against sequence-validated batches of nine SARS-CoV-2 variants. Further methodological details on mAbs, virus variants and culture, high-throughput live virus microneutralisation assays, and data analysis, statistics, and availability are available in the appendix.

This work was a benchmarking exercise between the Crick COVID Surveillance Unit and the Legacy study, an ongoing collaboration between University College London Hospitals and the Francis Crick Institute in
Correspondence

London, UK. Legacy was approved by the London Camden and Kings Cross Health Research Authority Research and Ethics committee (IRAS number 286469) and is sponsored by University College London.

We assayed a panel of mAbs: sotrovimab, casivirimab and imdevimab (sold as Ronapreve, Regeneron); and tixagevimab and cilgavimab (sold as Evusheld, AstraZeneca). EC\textsubscript{50} values were calculated by fitting a four-parameter dose–response curve to 288 independent data points, generated from 12 independent repeats of 12 independent titrations, each consisting of two technical replicates of a four-point dilution series against live SARS-CoV-2 variants (appendix p 2). This approach enabled refined determination of EC\textsubscript{50} values and corresponding 95% CIs (appendix pp 3–4). We found that sotrovimab, imdevimab, and cilgavimab neutralised omicron BA.2, BA.2.12.1, BA.4, and BA.5.

Many reports focus their narrative and data presentation on the reduction of neutralisation of a given mAb relative to ancestral SARS-CoV-2; however, this metric is less helpful in assessing efficacy since starting absolute titres versus ancestral virus vary widely, and mAbs formulation, dosing, and administration also vary. Similarly, in the absence of real-world efficacy data, consideration of the EC\textsubscript{50} value relative to pharmacokinetic data (eg, measured serum concentrations of mAbs post-administration) requires assumptions regarding tissue penetration and mechanism of action.

In this context, technical aspects of neutralisation assays matter: many laboratories continue to use ACE2-overexpressing cells, despite such cells showing an aberrant lack of neutralisation of SARS-CoV-2 by certain classes of mAbs (including sotrovimab\textsuperscript{11} and at a fundamental level, comparison across laboratories is hampered by the use of different cell lines that may be infected by SARS-CoV-2 variants to different extents. Here, calibration with the WHO International Standard for anti-SARS-CoV-2 immunoglobulin and reporting of neutralisation titres in International Units (appendix p 5) would be useful to facilitate such comparisons. Additionally, reporting of CIs (rather than point estimates) is essential to evaluate the significance of any possible changes in neutralisation—especially when considering EC\textsubscript{90} values, which lie close to the plateau of the dose–response curve and are inherently noisy, both in cell-based assays and in fitting of a dose–response curve.

With the emergence of the omicron BA.2 variant in early 2022, the US Food and Drug Administration (FDA) found a decrease in microneutralisation titre EC\textsubscript{90} of 25–48-fold relative to ancestral SARS-CoV-2.\textsuperscript{2} On April 5, 2022, the FDA withdrew approval of sotrovimab\textsuperscript{12} on the basis of their assay results and pharmacokinetic modelling suggesting that the authorised dose was unlikely to be effective against BA.2. In wider reporting, including medical literature,\textsuperscript{13} the prevailing (but, in our view, erroneous) view became that sotrovimab is ineffective against BA.2 and BA.5, with the dose aspect of the FDA’s statement set aside.

We found that sotrovimab neutralised BA.2 with an EC\textsubscript{50} of 1849 ng/mL (95% CI 1429–2391), representing a 22-fold reduction versus ancestral SARS-CoV-2, with the EC\textsubscript{90} remaining 64-fold below the mean peak serum concentration of sotrovimab (appendix p 6) and 13-fold below the mean serum concentration 28 days post-administration. These and other data led UK health authorities, in contrast to US health authorities, to retain sotrovimab for the treatment of extremely clinically vulnerable patients who are at risk of progression to severe COVID-19, given the absence of an alternative approved mAb and clinical data showing a reduction in real-world efficacy.

It remains challenging to integrate clinical trial results into these assessments. Most trials use a primary endpoint of a positive COVID-19 test since they recruit too few participants to power the statistical analysis of progression to severe disease, which would be the more relevant metric for clinical practice for extremely clinically vulnerable patients and for public health policy to reduce the burden on health-care infrastructure. However, large-scale analyses of digital primary care health records from the UK National Health Service, linking clinical outcomes with patient metadata, have recently shown that sotrovimab was superior to treatment with molnupiravir in preventing COVID-19-related hospitalisation and death in extremely clinically vulnerable populations during the period of the omicron BA.2 wave.\textsuperscript{7}

This demonstration of sotrovimab's efficacy against BA.2 can be used in conjunction with our in-vitro neutralisation data to conservatively infer real-world efficacy against emerging variants of concern: those that are neutralised to the same extent as, or even better than, BA.2 (numerically, a lower EC\textsubscript{90}) would be expected to remain effective. We found that sotrovimab neutralised BA.4, BA.5, and BA.2 to similar extents (EC\textsubscript{90}=1490 ng/mL; 95% CI 881–2517), suggesting that sotrovimab would remain effective against BA.5. Similarly, a second-generation BA.2 variant, BA.2.12.1, was neutralised to a greater extent than parental BA.2 (EC\textsubscript{90}=1211 ng/mL; 95% CI 844–1738), in line with preliminary pseudotyped lentivirus neutralisation data on a wider set of second-generation omicron sublineages, including BA.2.75.2.\textsuperscript{14} In light of this evidence, it would be reasonable to retain the use of sotrovimab, especially in extremely clinically vulnerable patients who test positive for COVID-19 and have few other options.

The lack of directionality in the degree of neutralisation by a mAb and successive variants is worth highlighting, perhaps most strikingly in the case of the imdevimab component of Ronapreve. As omicron spread in the
UK in December, 2021, we and others found that BA1 fully escaped from casirivimab–imdevimab in vitro,\textsuperscript{21–23} with no neutralisation whatsoever at concentrations up to 18 750 ng/mL. UK policy was then changed to restrict the usage of casirivimab–imdevimab to infection with a non-omicron variant on Dec 24, 2021, during the UK’s transition from delta to omicron BA1.\textsuperscript{18} However, we later found that the imdevimab component of Ronapreve was able to neutralise subsequent omicron BA.2, BA.2.12.2, BA.4, and BA.5 variants (appendix p 4). For BA.4 and BA.5, this value is 536-fold below the mean peak serum concentration and 92-fold below the mean serum concentration 28 days post-administration (appendix p 6), reflecting a greater degree of neutralisation by imdevimab than sotrovimab in vitro, despite only the latter remaining in clinical use.

Our results on imdevimab are consistent with other reports published in June–August, 2022.\textsuperscript{19–21} All together, the evidence does not support WHO’s decision in September, 2022, to withdraw conditional recommendation of casirivimab–imdevimab for seronegative patients. Regulators might need to re-evaluate withdrawn mAbs in light of evidence of regained activity against the spike protein of a future variant.

In the case of sotrovimab, the combined evidence from our in-vitro neutralisation and real-world clinical efficacy data supports its continued use against circulating omicron variants, including BA.4 and BA.5. The ongoing evolution of SARS-CoV-2 variants and continued global transmission has resulted in a situation where new variants can replace one another within weeks. Although WHO’s Living Guideline\textsuperscript{4} posits the “need for clinical trial evidence in order to confirm any clinical effectiveness of new monoclonal antibodies that reliably neutralize the circulating strains”, generating this evidence is challenging since the results would almost instantly become obsolete. This situation is compounded by the overall low rate of hospital admissions in the face of high levels of population immunity: trialists struggle to recruit sufficient participants to power analysis of efficacy of new therapies against progression to severe illness.

Overall, our results highlight how the regulatory environment for mAbs has not kept pace—a fact also illustrated by the ciligavimab component of Evusheld, which showed strong neutralisation against all omicron variants tested here (appendix p 4). Evusheld is now approved for treatment in Europe and Japan but remains approved only for prophylactic use in the USA and the UK, in part due to a dogmatic focus by some regulators on not licensing the same therapeutics for prophylaxis and treatment of acute COVID-19. Bebtelovimab (not studied here and not assessed in WHO’s Living Guideline\textsuperscript{4}) remains unavailable outside the USA,\textsuperscript{22,23} where the FDA adopted a more relaxed approach to Emergency Use Authorisation based on data showing improved symptoms and somewhat reduced viral loads from phase 1 and 2 trials together with in-vitro neutralisation data.\textsuperscript{24} That regulatory flexibility is limited: although long experience with antiviral therapies suggests mAb combination therapy (eg, across mAb classes or in combination with small-molecule antivirals) is preferable to monotherapy, the regulatory and commercial backdrop makes these kinds of cross-company trials challenging. The net result is that effective monoclonals are available but not offered to extremely clinically vulnerable patients with COVID-19 who are at risk of progressing to severe disease.

We recommend, first, that WHO’s Living Guideline\textsuperscript{4} be further updated to reflect the available data, and second, that more responsive regulatory approaches are developed to integrate high-quality, standardised live-virus neutralisation data with efficacy data from real-world clinical use. This approach might contribute positively towards determining an index of protection for a given mAb (or class of mAbs with shared Fc modifications considered as a single platform)—analogous to a correlate of protection for vaccine-induced antibodies.

At present there is an unrealistically high threshold to enter a therapeutic agent into clinical practice. The threshold to withhold or withdraw the same agent is much lower when based on in-vitro evidence for loss of potency alone. Such a situation disproportionately affects vulnerable patients whose other essential medications or comorbidities exclude COVID-19 therapeutics other than a neutralising mAb. This situation also strongly disincentivises development of novel antivirals that are needed to continue to offer protection to highly vulnerable populations.

CS reports interests unrelated to this Correspondence: grants from BMS, Ono Pharmaceuticals, Boehringer Ingelheim, Roche Ventana, Pfizer, and Archer Dx; personal fees from Genentech, Sarah Canon Research Institute, Medicix, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, IMS, Illumina, GlaxoSmithKline, MSD, and Roche-Ventana; and stock options from Apogen Biotech, Epic Biosciences, GRAIL, and Achilles Therapeutics. SGam reports funding from AstraZeneca to evaluate monoclonal antibodies subsequent to this work. MB is a local Principal Investigator on LUNAR, a GlaxoSmithKline sotrovimab monitoring study, with no personal financial reward. DLVB reports grants from AstraZeneca, unrelated to this Correspondence. DLVII is also a member of the Genotype to Phenotype UK National Virology Consortium. All other authors declare no competing interests. Funding details and acknowledgments can be found in the appendix. All data and full R code to produce all figures in the appendix are available online on Github.

Mary Y Wu, Edward J Carr, Ruth Harvey, Harriet V Mears, Svend Kjaer, Hermaleigh Townsley, Agnieszka Hobbs, Martina Ragni, Lou S Herman, Lorin Adams, Steve Gamblin, Michael Howell, Rupert Beale, Michael Brown, Bryan Williams, Sonia Gandhi, Charles Swanton, Emma C Wall, *David L V Bauer
david.bauer@crick.ac.uk

The Francis Crick Institute, London NW1 1AT, UK (MYW, EJC, HVM, SK, HT, AH, MR, LSH, SGam, MH,
Correspondence

1. UK Government Cabinet Office. COVID-19 response: living with COVID-19. May 6, 2022. https://www.gov.uk/government/publication/covid-19-response-living-with-covid-19/covid-19-response-living-with-covid-19 (accessed May 6, 2022).

2. Zheng B, Green ACA, Tazar J, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform. bioRxiv 2022; published online Sept 22. https://doi.org/10.1101/2022.05.22.2225417 (preprint).

3. WHO. Therapeutics and COVID-19: living guideline. July 14, 2022. https://apps.who.int/iris/bitstream/handle/10665/359774/WHO-2019-nCoV-therapeutics-2022.4-eng.pdf (accessed Sept 21, 2022).

4. WHO. Therapeutics and COVID-19: living guideline. Sept 16, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5 (accessed Sept 21, 2022).

5. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.621 and B.1.51 by BNT162b2 vaccination. Lancet 2021; 397: 2331–33.

6. Wall EC, Wu M, Harvey R, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 delta VOC. Lancet 2022; 398: 207–09.

7. Wu M, Wall EC, Carr EJ, et al. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet 2022; 399: 755–57.

8. Mattsson G, Bentley EM, Hassall M, et al. WHO/BS/2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. Nov 18, 2020. https://www.who.int/publications/m/item/WHO-BS/2020.2403 (accessed July 13, 2022).

9. Bentley EM, Atkinson E, Rigby P, et al. WHO/BS/2022.2427 Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern. July 19, 2022. https://www.who.int/publications/m/item/who-bs-2022-2427 (accessed Sept 21, 2022).

10. Lempp FA, Soriaga LB, Montiel-Ruiz M, et al. Lectins enhance SARS-CoV-2 infection and influence neutralising antibodies. Nature 2021; 598: 342–47.

11. US Food and Drug Administration. Fact sheet for healthcare providers Emergency Use Authorization (EUA) of sotrovimab authorized use. March 2022. https://www.fda.gov/media/149534/download (accessed May 6, 2022).

12. US Food and Drug Administration. FDA updates sotrovimab emergency use authorization. April 5, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization (accessed May 6, 2022).

13. Mahase E. Covid-19: has the spread of omicron BA.2 made antibody treatments redundant? BMJ 2022; 377: e10097.

14. Shewad DJ, Kim C, Fischbach J, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. bioRxiv 2022; published online Sept 19. https://doi.org/10.1101/2022.09.16.602839 (preprint).

15. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med 2022; 28: 329–32.

16. Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 2022; 185: 447–56.

17. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature 2021; 602: 761–75.

18. MHRA Central Alerting System. Neutralising monoclonal antibody and intravenous antiviral treatments for patients in hospital with COVID-19 infection. Dec 24, 2021. https://www.cas.mhra.gov.uk/ViewandAcknowledgeViewAlert.aspx?AlertID=103189 (accessed May 6, 2022).

19. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 2022; 387: 468–70.

20. Aurora P, Kempf A, Nehmeier I, et al. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect Dis 2022; 22: 1117–18.

21. Caño Y, Isimaya A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature 2022; 606: 593–602.

22. Hentziin M, Attmun B, Pirolo L, Yazdanpanah Y, Calmy A. A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to belbetalovimab. Lancet Infect Dis 2022; 22: 1278–80.

23. Nichols RA, DeVoe C, Udugama Y, Belbetalovimab: considerations for global access to treatments during a rapidly evolving pandemic. Lancet Infect Dis 2022; published online Sept 26. https://doi.org/10.1016/S1473-3099(22)00592-8.

24. US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for belbetalovimab. September 2022. https://www.fda.gov/media/155612/download (accessed Sept 30, 2022).

WHO Living Guidelines on antivirals for COVID-19 are evidence-based

Mary Wu and colleagues suggest a change to WHO’s COVID-19 treatment guidelines for monoclonal antibodies. These Living Guidelines were updated on Sept 16, 2022, with strong recommendations against the use of sotrovimab and casirivimab-imecvimab following the emergence of new SARS-CoV-2 variants and subvariants. We, as members of the WHO panel responsible for presenting the evidence to the Guideline Development Group (GDG), welcome this opportunity to elaborate on the evidence considered during the GDG meeting.

Wu and colleagues present in-vitro data that provide further evidence that neutralisation is equivalent for sotrovimab between BA.2, BA.4, and BA.5 monoclonal lines. Their findings support interpretation of the data considered during development of the guideline that led the GDG to conclude similar reduction in neutralisation between these sublineages. However, Wu and colleagues present an over-simplistic assessment of the neutralisation data in the context of the compartmental pharmacokinetics of monoclonal antibodies. As a result, Wu and colleagues make incorrect inferences regarding the interpretation of the in-vitro neutralisation data in the context of clinical effectiveness. When appropriately assessed, the new data does not change the basis on which the original decision to recommend against sotrovimab was made. Although neutralisation of these lineages via sotrovimab appears equivalent and lower than previous variants, it is also insufficient to confer the clinical effectiveness of sotrovimab reported in the pre-omicron era.

The analysis presented to the GDG during their deliberations included arguments presented by the US Food and Drug Administration for the use of sotrovimab—arguments that Wu and colleagues neither acknowledged nor rebutted. Specifically, this analysis included two aspects. First, as per antiviral pharmacology convention, when serum concentrations are corrected for penetration into the lung, the target concentrations (defined by the effective concentration required for 90% neutralisation [EC90] of BA.2 omicron) are unlikely to be achieved. Second, applying an EC90 fold-change.